Physical and chemical evaluation of liposomes, containing artesunate

被引:49
作者
Gabriëls, M [1 ]
Plaizier-Vercammen, J [1 ]
机构
[1] Free Univ Brussels, Inst Pharmaceut, B-1090 Brussels, Belgium
关键词
liposomes; artesunate; sterile production; malaria;
D O I
10.1016/S0731-7085(02)00678-7
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
As artesunate has a rapid onset of therapeutic effect and quick elimination, frequent administration is required, especially in the treatment of malaria. Such treatment courses led to bad patients' compliance, leading to high recrudescence rate. Therefore, slow release preparations seemed to be a logical approach in artesunate monotherapies, as can be developed with liposomal suspensions, especially for parenteral administration. Thus, the aim of this study was to develop sterile liposomes. The suspension was evaluated on its chemical/physical stability, including chemical degradation and crystallization of artesunate, and release capacities, by use of the dialysis technique. The maximal encapsulation degree of artesunate without crystals was 1.5 mg in 300 mg lipids per ml suspension, containing egg-phosphatidylcholine/cholesterol in a molar ratio of 4:3. The highest stability was obtained with a phosphate buffer of pH 5, which could be expected, as artesunate is almost totally encapsulated. But by reason of instability in water, the suspension containing artesunate 1 mg/ml was preferred, as the encapsulation efficiency is 100%. The in vitro release test proves that artesunate is reversibly encapsulated in liposomes. A method for sterile production of liposomes at lab-scale level is also presented. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:655 / 667
页数:13
相关论文
共 41 条
[11]   LIPOSOME-ASSOCIATED RETINOIDS - PRODUCTION, CHARACTERIZATION AND ANTIPROLIFERATIVE ACTIVITY ON NEOPLASTIC-CELLS [J].
CORTESI, R ;
ESPOSITO, E ;
GAMBARI, R ;
MENEGATTI, E ;
NASTRUZZI, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 2 (04) :281-291
[12]   ACTIVE TARGETING WITH PARTICULATE CARRIER SYSTEMS IN THE BLOOD COMPARTMENT [J].
CROMMELIN, DJA ;
SCHERPHOF, G ;
STORM, G .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 17 (01) :49-60
[13]   INTERACTION OF TAXOL AND OTHER ANTICANCER DRUGS WITH ALPHA-CYCLODEXTRIN [J].
CSERHATI, T ;
FORGACS, E ;
HOLLO, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (4-5) :533-541
[14]   Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria [J].
Davis, TME ;
Phuong, HL ;
Ilett, KF ;
Hung, NC ;
Batty, KT ;
Phuong, VDB ;
Powell, SM ;
Thien, HV ;
Binh, TQ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :181-186
[15]  
FIUME Z, 2000, INT J TOXICOL, V20, P21
[16]  
Gabriëls M, 2000, J AOAC INT, V83, P589
[17]  
GREGORIADIS G, 1993, LIPOSOME TECHNOLOGY, V1
[18]   Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits [J].
Groll, AH ;
Petraitis, V ;
Petraitiene, R ;
Field-Ridley, A ;
Calendario, M ;
Bacher, J ;
Piscitelli, SC ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2463-2467
[19]  
Kadir F, 1993, PHARM PARTICULATE CA, P165
[20]   Pharmacokinetics of oral artesunate in Thai patients with uncomplicated falciparum malaria [J].
Karbwang, J ;
Na-Bangchang, K ;
Congpoung, K ;
Thanavibul, A ;
Harinasuta, T .
CLINICAL DRUG INVESTIGATION, 1998, 15 (01) :37-43